Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free ZIVO Stock Alerts

ZIVO Bioscience (ZIVO) Financials

ZIVO Bioscience logo
$4.00 0.00 (0.00%)
As of 07/21/2026 01:59 PM Eastern
Compare
Annual Income Statements for ZIVO Bioscience

Annual Income Statements for ZIVO Bioscience

This table shows ZIVO Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 9.64 -4.16 -6.06 -10 -15 -12 -9.66 -8.76 -8.75 -7.78 -13
Consolidated Net Income / (Loss)		 0.68 -5.79 -6.06 -10 -15 -12 -9.11 -8.76 -8.75 -7.78 -13
Net Income / (Loss) Continuing Operations		 9.64 -4.16 -6.06 -10 -15 -12 -9.66 -8.76 -8.75 -7.78 -13
Total Pre-Tax Income 		9.64 -4.16 -6.06 -10 -15 -12 -9.11 -8.76 -8.75 -7.78 -13
Total Operating Income		 -5.15 -3.06 -3.49 -6.33 -6.13 -8.35 -8.56 -8.65 -8.73 -7.26 -13
Total Gross Profit		 1.48 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.01 0.05
Total Revenue		 1.48 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.03 0.16
Operating Revenue		 1.48 0.00 0.00 - 0.00 0.00 0.02 0.00 0.00 0.03 0.16
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.11
Operating Cost of Revenue		 - - - - - - - - 0.00 0.02 0.11
Total Operating Expenses		 -1.95 3.06 3.49 6.33 6.13 8.35 8.58 8.65 8.73 7.27 13
Selling, General & Admin Expense		 1.91 2.02 0.83 2.13 1.35 4.08 4.82 6.69 6.49 5.90 10
Research & Development Expense		 1.97 1.03 0.79 2.38 2.81 2.31 3.75 1.95 2.24 1.38 3.13
Total Other Income / (Expense), net		 6.20 -1.10 -2.57 -3.71 -8.50 -3.16 -0.55 -0.11 -0.01 -0.51 -0.02
Interest Expense		 2.31 -0.72 2.36 3.36 8.10 3.16 0.55 0.11 0.01 0.51 0.02
Weighted Average Basic Shares Outstanding		 125.33M 130.95M 133.84M 139.24M 156.68M 276.40M 5.08M 7.63M 1.57M 1.69M 3.76M
Diluted Earnings per Share		 - ($0.04) ($0.05) ($0.07) ($0.09) ($0.04) ($1.79) - ($5.57) ($4.60) ($4.23)
Weighted Average Diluted Shares Outstanding		 182.21M 130.95M 133.84M 139.24M 156.68M 276.40M 5.08M 7.63M 1.57M 1.69M 3.17M
Weighted Average Basic & Diluted Shares Outstanding		 182.21M 130.95M 133.84M 139.24M 156.68M 276.40M 5.08M 7.63M 1.57M 1.69M 3.76M

Quarterly Income Statements for ZIVO Bioscience

This table shows ZIVO Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.82 -1.91 -1.28 -8.24 -2.27 -1.60 -4.21 -1.64 -1.03
Consolidated Net Income / (Loss)		 -1.82 -1.91 -1.28 -8.24 -2.27 -1.60 -4.21 -1.64 -1.03
Net Income / (Loss) Continuing Operations		 -1.82 -1.91 -1.28 -8.24 -2.27 -1.60 -4.21 -1.64 -1.03
Total Pre-Tax Income 		-1.82 -1.91 -1.28 -8.24 -2.27 -1.60 -4.21 -1.64 -1.03
Total Operating Income		 -1.57 -1.90 -1.28 -8.23 -2.26 -1.60 -4.21 -1.63 -1.02
Total Gross Profit		 0.00 0.00 0.01 0.00 0.01 0.03 0.00 0.02 0.02
Total Revenue		 0.01 0.01 0.04 0.00 0.03 0.09 0.00 0.05 0.07
Operating Revenue		 0.01 0.01 0.04 0.00 0.03 0.09 0.00 0.05 0.07
Total Cost of Revenue		 0.01 0.01 0.02 0.00 0.02 0.06 0.00 0.04 0.04
Operating Cost of Revenue		 0.01 0.01 0.02 0.00 0.02 0.06 0.00 0.04 0.04
Total Operating Expenses		 1.58 1.90 1.29 8.23 2.27 1.62 4.21 1.65 1.04
Selling, General & Admin Expense		 1.36 1.59 0.98 5.98 1.94 1.38 1.44 1.17 0.84
Research & Development Expense		 0.22 0.31 0.31 2.25 0.33 0.24 2.77 0.48 0.20
Total Other Income / (Expense), net		 -0.25 -0.01 -0.00 -0.01 -0.01 -0.00 -0.00 -0.01 -0.01
Interest Expense		 0.25 0.01 0.00 0.01 0.01 0.00 0.00 0.01 0.01
Other Income / (Expense), net		 - - - - 0.00 - - - -0.00
Weighted Average Basic Shares Outstanding		 1.74M 1.69M 2.75M 2.96M 3.41M 3.76M 3.81M 3.82M 3.89M
Diluted Earnings per Share		 ($1.05) ($1.13) ($0.47) ($2.78) ($0.67) ($0.43) ($1.12) ($0.43) ($0.27)
Weighted Average Diluted Shares Outstanding		 1.74M 1.69M 2.75M 2.96M 3.41M 3.17M 3.75M 3.81M 3.82M
Weighted Average Basic & Diluted Shares Outstanding		 1.74M 1.69M 2.75M 2.96M 3.41M 3.76M 3.81M 3.82M 3.89M

Annual Cash Flow Statements for ZIVO Bioscience

This table details how cash moves in and out of ZIVO Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -0.49 0.02 0.49 -0.19 0.07 -0.04 -0.21 8.76 11 -1.52 1.27
Net Cash From Operating Activities		 -2.74 -2.30 -2.54 -4.24 -5.01 -3.71 -2.59 -6.80 -7.10 -5.80 -4.31
Net Cash From Continuing Operating Activities		 14 -6.31 -2.54 -4.24 -5.01 -3.71 -2.58 -6.86 11 -5.80 -4.31
Net Income / (Loss) Continuing Operations		 0.68 -5.79 -6.06 -10 -15 -12 -9.11 -8.76 8.75 -7.78 -13
Consolidated Net Income / (Loss)		 0.68 -5.79 -6.06 -10 -15 -12 -9.11 -8.76 8.75 -7.78 -13
Amortization Expense		 1.81 1.87 1.40 1.26 6.00 1.56 0.00 -0.56 0.00 -0.17 0.10
Non-Cash Adjustments To Reconcile Net Income		 -6.67 0.64 1.45 3.17 1.70 3.77 5.68 2.90 2.77 0.94 9.41
Changes in Operating Assets and Liabilities, net		 1.43 0.96 0.64 1.35 1.94 2.47 0.85 -0.45 -0.36 1.21 -0.44
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 2.24 2.31 3.03 4.05 5.08 3.66 2.38 16 0.00 4.28 5.58
Net Cash From Continuing Financing Activities		 2.24 2.31 3.03 4.05 5.08 3.66 2.38 16 0.00 4.28 5.58
Repayment of Debt		 -0.00 - -0.22 -0.10 -0.11 - 0.00 -0.19 -0.63 -0.61 -0.54
Issuance of Debt		 1.51 2.07 3.25 4.15 1.97 - 0.95 0.19 0.63 4.24 0.52
Issuance of Common Equity		 0.74 0.05 - 0.00 3.43 2.65 0.40 17 - 0.16 4.28
Other Financing Activities, net		 - 0.20 - - -0.22 1.01 1.03 -1.64 0.00 0.49 1.32
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.07 0.02
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for ZIVO Bioscience

This table details how cash moves in and out of ZIVO Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Net Change in Cash & Equivalents		 3.12 -2.87 -0.14 -0.14 0.16 1.24 -1.03 -0.51 0.05
Net Cash From Operating Activities		 -1.97 -0.72 -1.70 -0.62 -1.09 -0.91 -1.43 -0.48 -0.27
Net Cash From Continuing Operating Activities		 0.04 -2.69 -1.70 -0.62 -1.09 -1.17 -1.43 -0.48 -0.27
Net Income / (Loss) Continuing Operations		 -1.82 -1.91 -1.28 -8.24 9.51 -1.60 -4.21 -1.64 5.85
Non-Cash Adjustments To Reconcile Net Income		 0.78 0.16 0.11 7.21 -10 0.61 3.12 0.26 -6.55
Changes in Operating Assets and Liabilities, net		 0.24 0.29 -0.53 0.41 -0.22 -0.27 -0.34 0.90 0.43
Net Cash From Financing Activities		 3.43 -0.49 1.56 0.49 1.24 2.29 0.40 -0.03 0.31
Net Cash From Continuing Financing Activities		 3.12 -0.18 1.56 0.49 1.24 2.40 0.40 -0.03 0.31
Repayment of Debt		 -0.20 -0.13 -0.06 0.06 -0.40 -0.14 -0.08 0.01 -0.38
Issuance of Debt		 - 2.63 0.52 - - - 0.49 - 0.25
Other Financing Activities, net		 - 0.80 0.13 0.43 0.61 1.43 0.00 -0.15 0.44
Cash Interest Paid		 0.01 0.06 0.00 0.01 0.01 0.00 0.00 0.01 -0.00

Annual Balance Sheets for ZIVO Bioscience

This table presents ZIVO Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 0.10 0.07 0.74 0.33 0.41 0.37 0.22 8.99 2.12 0.56 1.64
Total Current Assets		 0.03 0.03 0.52 0.33 0.41 0.37 0.17 8.96 1.90 0.43 1.64
Cash & Equivalents		 0.00 0.02 0.51 0.32 0.39 0.35 0.14 8.90 1.80 0.27 1.54
Accounts Receivable		 - - - - - - - - 0.00 0.00 0.00
Prepaid Expenses		 0.03 0.01 0.01 0.02 0.02 0.02 0.03 0.06 0.10 0.15 0.09
Plant, Property, & Equipment, net		 0.07 0.04 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.20 0.00 0.00 0.00 0.05 0.03 0.22 0.13 0.01
Other Noncurrent Operating Assets		 - 0.00 0.20 - - 0.00 0.05 0.03 0.22 0.13 0.01
Total Liabilities & Shareholders' Equity		 0.10 0.07 0.74 0.33 0.41 0.37 0.22 8.99 2.12 0.56 1.64
Total Liabilities		 6.47 9.57 14 17 23 8.71 12 2.95 2.13 2.76 2.16
Total Current Liabilities		 6.23 4.97 11 4.56 23 8.71 11 2.95 2.03 2.76 2.04
Short-Term Debt		 0.14 1.56 - - - 0.00 0.04 0.02 0.10 0.11 0.14
Accounts Payable		 1.23 1.33 0.99 1.02 0.85 1.37 1.56 0.65 0.49 1.17 0.74
Accrued Expenses		 1.24 0.41 0.40 0.01 0.01 0.10 0.21 0.47 0.40 1.15 1.10
Customer Deposits		 - - - - - - - - - - 0.00
Other Current Liabilities		 3.63 - 7.13 1.88 18 5.28 5.18 0.24 0.24 0.24 0.00
Other Current Nonoperating Liabilities		 - 1.67 2.66 1.65 3.67 1.95 2.46 0.10 0.10 0.10 0.07
Total Noncurrent Liabilities		 0.24 4.60 3.18 12 0.00 0.00 0.14 0.00 0.11 0.00 0.12
Long-Term Debt		 0.24 4.60 - - - 0.00 0.12 - - - 0.12
Other Noncurrent Operating Liabilities		 - - 3.18 12 - 0.00 0.02 0.00 0.11 0.00 0.00
Total Equity & Noncontrolling Interests		 -6.37 -9.50 -14 -16 -22 -8.34 -11 6.04 -0.01 -2.21 -0.51
Total Preferred & Common Equity		 -6.37 -9.50 -14 -16 -22 -8.34 -11 6.04 -0.01 -2.21 -0.51
Total Common Equity		 -6.37 -9.50 -14 -16 -22 -8.34 -11 6.04 -0.01 -2.21 -0.51
Common Stock		 36 38 40 48 56 82 88 113 116 121 136
Retained Earnings		 -42 -48 -54 -64 -78 -90 -99 -107 -116 -124 -137

Quarterly Balance Sheets for ZIVO Bioscience

This table presents ZIVO Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 2.10 0.82 0.58 0.50 1.33 0.70 0.56
Total Current Assets		 1.95 0.71 0.50 0.44 1.02 0.41 0.28
Cash & Equivalents		 1.48 0.14 0.00 0.16 0.52 0.01 0.06
Accounts Receivable		 0.00 0.00 0.00 0.03 0.00 0.03 0.00
Prepaid Expenses		 0.46 0.57 0.49 0.25 0.51 0.37 0.22
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.15 0.11 0.08 0.06 0.31 0.29 0.28
Other Noncurrent Operating Assets		 0.15 0.11 0.08 0.06 0.31 0.29 0.28
Total Liabilities & Shareholders' Equity		 2.10 0.82 0.58 0.50 1.33 0.70 0.56
Total Liabilities		 3.20 3.09 2.87 2.58 2.95 3.24 3.85
Total Current Liabilities		 3.17 3.09 2.87 2.58 2.61 2.96 3.61
Short-Term Debt		 0.11 0.08 0.05 0.02 0.58 0.20 0.44
Accounts Payable		 0.64 0.92 1.17 0.92 0.66 0.93 1.33
Accrued Expenses		 0.82 1.29 1.00 1.13 1.22 1.43 1.61
Customer Deposits		 - - 0.02 0.05 0.03 0.03 0.02
Other Current Liabilities		 1.37 0.70 0.53 0.36 0.06 0.29 0.15
Other Current Nonoperating Liabilities		 0.15 0.10 0.10 0.10 0.07 0.07 0.07
Total Noncurrent Liabilities		 0.02 0.00 0.00 0.00 0.34 0.28 0.23
Long-Term Debt		 - - - - 0.08 0.05 0.01
Other Noncurrent Operating Liabilities		 - 0.00 0.00 0.00 - 0.24 0.22
Total Equity & Noncontrolling Interests		 -1.09 -2.27 -2.30 -2.08 -1.62 -2.54 -3.29
Total Preferred & Common Equity		 -1.09 -2.27 -2.30 -2.08 -1.62 -2.54 -3.29
Total Common Equity		 -1.09 -2.27 -2.30 -2.08 -1.62 -2.54 -3.29
Common Stock		 121 123 131 133 140 140 141
Retained Earnings		 -122 -125 -133 -135 -141 -143 -144

Annual Metrics And Ratios for ZIVO Bioscience

This table displays calculated financial ratios and metrics derived from ZIVO Bioscience's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
DEI Shares Outstanding		 128,561,904.00 132,049,700.00 136,745,349.00 140,906,061.00 169,000,743.00 358,751,762.00 409,586,542.00 18,839,320.00 9,419,660.00 1,819,523.00 3,546,335.00
DEI Adjusted Shares Outstanding		 128,561,904.00 132,049,700.00 136,745,349.00 140,906,061.00 169,000,743.00 358,751,762.00 409,586,542.00 18,839,320.00 9,419,660.00 1,819,523.00 3,546,335.00
DEI Earnings Per Adjusted Shares Outstanding		 0.07 -0.03 -0.04 -0.07 -0.09 -0.03 -0.02 -0.46 -0.93 -4.27 -3.77
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 468.61%
EBITDA Growth		 256.74% -157.55% 23.99% -137.93% 89.97% -1,153.19% -26.01% -7.54% 5.10% 14.87% -78.42%
EBIT Growth		 143.86% -245.33% 24.19% -80.75% 2.16% -27.75% -2.43% -1.05% -1.00% 16.82% -83.97%
NOPAT Growth		 -136.69% 58.48% -14.21% -81.36% 3.15% -36.24% -2.43% -1.05% -1.00% 16.82% -83.97%
Net Income Growth		 106.74% -950.33% -4.67% -65.66% -45.79% 21.35% 20.89% 3.84% 0.12% 11.07% -72.10%
EPS Growth		 0.00% 0.00% -25.00% -40.00% -28.57% 55.56% -4,375.00% 0.00% 0.00% 17.41% 8.04%
Operating Cash Flow Growth		 8.38% 16.05% -10.74% -66.81% -18.00% 25.95% 30.18% -162.84% -4.40% 18.34% 25.63%
Free Cash Flow Firm Growth		 -345.46% -18.62% 213.85% -112.63% 71.21% -6,683.92% 78.48% -211.18% 40.23% 38.98% -117.82%
Invested Capital Growth		 4.55% 71.97% -582.73% -30.55% -26.88% 64.56% -31.07% 68.85% 41.34% -40.99% 12.38%
Revenue Q/Q Growth		 1.18% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 74.45% 98.96%
EBITDA Q/Q Growth		 121.63% -235.77% 34.03% -51.20% 75.67% -113.51% 19.09% -33.13% 13.88% -7.03% 11.47%
EBIT Q/Q Growth		 242.56% -2,152.25% 26.59% -52.19% 13.08% -34.79% 19.09% -19.06% 5.43% 9.26% 2.20%
NOPAT Q/Q Growth		 5.83% 25.65% 0.60% -44.66% 13.78% -34.79% 19.09% -19.06% 5.43% 9.26% 2.20%
Net Income Q/Q Growth		 215.54% -43.11% -3.67% -35.83% 5.08% -9.88% 19.73% -16.60% 5.40% 8.61% 2.24%
EPS Q/Q Growth		 0.00% 0.00% -25.00% -40.00% 18.18% 20.00% -92.47% 0.00% 5.40% 6.12% -9.59%
Operating Cash Flow Q/Q Growth		 15.36% -8.95% -15.08% -14.66% 4.54% 11.32% -10.70% -17.23% 6.01% 11.20% -4.61%
Free Cash Flow Firm Q/Q Growth		 -2.18% -14,047.72% 555.57% -108.26% 93.96% -24.15% 68.30% -114.21% 9.40% 6.00% 1.11%
Invested Capital Q/Q Growth		 -13,648.98% 43.39% -200.77% 17.28% -1.81% 19.93% -150.97% 6.43% -15.19% 1.04% 5.96%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 41.99% 31.14%
EBITDA Margin		 349.34% 0.00% 0.00% 0.00% 0.00% 0.00% -42,778.38% 0.00% 0.00% -26,885.16% -8,436.34%
Operating Margin		 -347.02% 0.00% 0.00% 0.00% 0.00% 0.00% -42,778.38% 0.00% 0.00% -26,267.67% -8,498.85%
EBIT Margin		 226.00% 0.00% 0.00% 0.00% 0.00% 0.00% -42,778.38% 0.00% 0.00% -26,267.67% -8,498.85%
Profit (Net Income) Margin		 45.85% 0.00% 0.00% 0.00% 0.00% 0.00% -45,528.65% 0.00% 0.00% -28,127.25% -8,513.44%
Tax Burden Percent		 7.07% 139.28% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 287.10% 85.22% 163.90% 150.21% 223.85% 137.81% 106.43% 101.28% 100.15% 107.08% 100.17%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -8.53% 72.97% 52.42% 67.09% 75.86% 75.18% 92.68% 332.39% -289.98% 701.76% 983.91%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 294.87% 0.00% 0.00% 0.00% 0.00% 0.00% -2,902.33% 0.00% 0.00% -542.27% -1,215.36%
Return on Assets (ROA)		 59.82% 0.00% 0.00% 0.00% 0.00% 0.00% -3,088.93% 0.00% 0.00% -580.66% -1,217.45%
Return on Common Equity (ROCE)		 -8.53% 72.97% 52.42% 67.09% 75.86% 75.18% 92.68% 332.39% -289.98% 701.76% 983.91%
Return on Equity Simple (ROE_SIMPLE)		 -10.69% 60.96% 44.49% 61.57% 65.68% 138.04% 80.51% -144.91% 0.00% 352.57% 2,599.52%
Net Operating Profit after Tax (NOPAT)		 -5.15 -2.14 -2.44 -4.43 -4.29 -5.85 -5.99 -6.05 -6.11 -5.08 -9.35
NOPAT Margin		 -347.02% 0.00% 0.00% 0.00% 0.00% 0.00% -29,944.86% 0.00% 0.00% -18,387.37% -5,949.20%
Net Nonoperating Expense Percent (NNEP)		 -316.03% 89.08% 72.55% 321.82% 448.04% 231.55% 152.29% -85.80% -50.67% -322.70% -522.16%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - 242.16% 1,816.54%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 58.01% 68.86%
SG&A Expenses to Revenue		 128.57% 0.00% 0.00% 0.00% 0.00% 0.00% 24,103.81% 0.00% 0.00% 21,329.45% 6,536.01%
R&D to Revenue		 132.74% 0.00% 0.00% 0.00% 0.00% 0.00% 18,774.57% 0.00% 0.00% 4,980.21% 1,993.98%
Operating Expenses to Revenue		 -131.56% 0.00% 0.00% 0.00% 0.00% 0.00% 42,878.38% 0.00% 0.00% 26,309.66% 8,529.99%
Earnings before Interest and Taxes (EBIT)		 3.36 -4.88 -3.70 -6.68 -6.54 -8.35 -8.56 -8.65 -8.73 -7.26 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 5.19 -2.99 -2.27 -5.40 -0.54 -6.79 -8.56 -9.20 -8.73 -7.43 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.62 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.62 0.00 0.00 0.00
Price to Revenue (P/Rev)		 18.41 0.00 0.00 0.00 0.00 0.00 27.87 0.00 0.00 40.95 226.23
Price to Earnings (P/E)		 2.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 35.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 18.66 0.00 0.00 0.00 0.00 0.00 28.97 0.00 0.00 34.87 216.41
Enterprise Value to EBITDA (EV/EBITDA)		 5.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 8.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 2.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.06 -0.65 0.00 0.00 0.00 0.00 -0.01 0.00 -9.34 -0.05 0.00
Long-Term Debt to Equity		 -0.04 -0.48 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00
Financial Leverage		 -0.23 -0.52 -0.43 -0.12 -0.12 -0.16 -0.21 1.20 -1.72 0.75 0.57
Leverage Ratio		 -0.14 -0.01 -0.04 -0.04 -0.02 -0.03 -0.03 -1.75 1.84 -1.21 -0.81
Compound Leverage Factor		 -0.41 -0.01 -0.06 -0.05 -0.04 -0.04 -0.03 -1.77 1.85 -1.29 -0.81
Debt to Total Capital		 -6.31% -184.63% 0.00% 0.00% 0.00% 0.00% -1.43% 0.25% 111.98% -5.07% 0.00%
Short-Term Debt to Total Capital		 -2.35% -46.80% 0.00% 0.00% 0.00% 0.00% -0.34% 0.25% 111.98% -5.07% 0.00%
Long-Term Debt to Total Capital		 -3.96% -137.83% 0.00% 0.00% 0.00% 0.00% -1.09% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 106.31% 284.63% 100.00% 100.00% 100.00% 100.00% 101.43% 99.75% -11.98% 105.07% 100.00%
Debt to EBITDA		 0.07 -2.06 0.00 0.00 0.00 0.00 -0.02 0.00 -0.01 -0.01 0.00
Net Debt to EBITDA		 0.07 -2.06 0.00 0.00 0.00 0.00 0.00 0.97 0.19 0.02 0.00
Long-Term Debt to EBITDA		 0.05 -1.54 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.07 -2.88 0.00 0.00 0.00 0.00 -0.03 0.00 -0.02 -0.02 0.00
Net Debt to NOPAT		 -0.07 -2.87 0.00 0.00 0.00 0.00 0.00 1.47 0.28 0.03 0.00
Long-Term Debt to NOPAT		 -0.05 -2.15 0.00 0.00 0.00 0.00 -0.02 0.00 0.00 0.00 0.00
Altman Z-Score		 -523.47 -1,220.91 -135.17 -349.75 -383.68 -439.50 -819.19 -14.59 -83.39 -359.22 -133.85
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.01 0.01 0.05 0.07 0.02 0.04 0.01 3.04 0.94 0.15 0.80
Quick Ratio		 0.00 0.00 0.05 0.07 0.02 0.04 0.01 3.02 0.89 0.10 0.76
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.44 -6.45 7.35 -0.93 -0.27 -18 -3.90 -12 -7.25 -4.42 -9.63
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -2.35 0.00 3.11 -0.28 -0.03 -5.74 -7.08 -109.49 -544.23 -8.60 -420.02
Operating Cash Flow to Interest Expense		 -1.18 0.00 -1.08 -1.26 -0.62 -1.17 -4.71 -61.42 -533.27 -11.28 -188.04
Operating Cash Flow Less CapEx to Interest Expense		 -1.18 0.00 -1.08 -1.26 -0.62 -1.17 -4.71 -61.42 -533.27 -11.28 -188.04
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.30 0.00 0.00 0.00 0.00 0.00 0.07 0.00 0.00 0.02 0.14
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 52.88
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.11
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.90
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 18,846.54 3,215.53
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -18,846.54 -3,208.63
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.99 -1.68 -11 -15 -19 -6.73 -8.82 -2.75 -1.61 -2.27 -1.99
Invested Capital Turnover		 -0.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.07
Increase / (Decrease) in Invested Capital		 0.29 4.31 -9.79 -3.50 -4.02 12 -2.09 6.08 1.14 -0.66 0.28
Enterprise Value (EV)		 28 26 20 21 23 45 0.58 13 22 0.96 34
Market Capitalization		 27 20 20 21 24 46 0.56 22 24 1.13 36
Book Value per Share		 ($0.05) ($0.07) ($0.10) ($0.12) ($0.13) ($0.02) ($0.03) $0.66 $0.00 ($1.21) ($0.15)
Tangible Book Value per Share		 ($0.05) ($0.07) ($0.10) ($0.12) ($0.13) ($0.02) ($0.03) $0.66 $0.00 ($1.21) ($0.15)
Total Capital		 -5.99 -3.34 -14 -16 -22 -8.34 -11 6.06 0.09 -2.10 -0.51
Total Debt		 0.38 6.16 0.00 0.00 0.00 0.00 0.16 0.02 0.10 0.11 0.00
Total Long-Term Debt		 0.24 4.60 0.00 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00
Net Debt		 0.38 6.14 -0.51 -0.32 -0.39 -0.35 0.02 -8.89 -1.70 -0.17 -1.54
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.06 -3.40 -11 -4.55 -23 -8.68 -11 -2.87 -1.83 -2.50 -1.95
Debt-free Net Working Capital (DFNWC)		 -6.06 -3.38 -11 -4.23 -22 -8.34 -11 6.03 -0.03 -2.23 -0.41
Net Working Capital (NWC)		 -6.20 -4.94 -11 -4.23 -22 -8.34 -11 6.01 -0.13 -2.34 -0.41
Net Nonoperating Expense (NNE)		 -5.83 3.65 3.62 5.61 10 5.66 3.12 2.70 2.63 2.69 4.03
Net Nonoperating Obligations (NNO)		 0.38 7.82 2.15 1.33 3.29 1.61 2.49 -8.79 -1.60 -0.07 -1.48
Total Depreciation and Amortization (D&A)		 1.83 1.89 1.43 1.28 6.00 1.56 0.00 -0.56 0.00 -0.17 0.10
Debt-free, Cash-free Net Working Capital to Revenue		 -408.17% 0.00% 0.00% 0.00% 0.00% 0.00% -56,628.95% 0.00% 0.00% -9,056.85% -1,239.55%
Debt-free Net Working Capital to Revenue		 -408.08% 0.00% 0.00% 0.00% 0.00% 0.00% -55,939.64% 0.00% 0.00% -8,064.52% -258.48%
Net Working Capital to Revenue		 -417.58% 0.00% 0.00% 0.00% 0.00% 0.00% -56,130.50% 0.00% 0.00% -8,449.12% -258.48%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.06 $0.00 ($0.30) ($0.42) ($0.54) ($0.24) ($0.12) ($7.20) ($5.58) ($4.60) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 20.89M 21.82M 22.83M 23.53M 30.01M 67.03M 69.72M 1.27M 1.57M 2.78M 3.76M
Adjusted Diluted Earnings per Share		 $0.06 $0.00 ($0.30) ($0.42) ($0.54) ($0.24) ($0.12) ($7.20) ($5.58) ($4.60) ($4.23)
Adjusted Weighted Average Diluted Shares Outstanding		 21.62M 22.11M 22.83M 23.53M 30.01M 67.03M 69.72M 1.27M 1.57M 2.78M 3.17M
Adjusted Basic & Diluted Earnings per Share		 $0.06 $0.00 ($0.30) ($0.42) ($0.54) ($0.24) ($0.12) ($7.20) ($5.58) ($4.60) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 30.37M 21.82M 22.31M 23.21M 26.11M 46.07M 67.70M 1.27M 1.57M 1.69M 3.76M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.61 -2.14 -2.44 -4.43 -4.29 -5.85 -5.99 -6.05 -6.11 -5.08 -9.35
Normalized NOPAT Margin		 -242.91% 0.00% 0.00% 0.00% 0.00% 0.00% -29,944.86% 0.00% 0.00% -18,387.37% -5,949.20%
Pre Tax Income Margin		 648.85% 0.00% 0.00% 0.00% 0.00% 0.00% -45,528.65% 0.00% 0.00% -28,127.25% -8,513.44%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 1.45 0.00 -1.57 -1.99 -0.81 -2.65 -15.55 -78.05 -655.60 -14.13 -582.50
NOPAT to Interest Expense		 -2.23 0.00 -1.03 -1.32 -0.53 -1.85 -10.89 -54.64 -458.92 -9.89 -407.75
EBIT Less CapEx to Interest Expense		 1.45 0.00 -1.57 -1.99 -0.81 -2.65 -15.55 -78.05 -655.60 -14.13 -582.50
NOPAT Less CapEx to Interest Expense		 -2.23 0.00 -1.03 -1.32 -0.53 -1.85 -10.89 -54.64 -458.92 -9.89 -407.75
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for ZIVO Bioscience

This table displays calculated financial ratios and metrics derived from ZIVO Bioscience's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
DEI Shares Outstanding		 10,449,660.00 1,819,523.00 2,777,639.00 2,831,943.00 3,366,112.00 3,546,335.00 3,759,213.00 3,813,517.00 3,817,005.00
DEI Adjusted Shares Outstanding		 10,449,660.00 1,819,523.00 2,777,639.00 2,831,943.00 3,366,112.00 3,546,335.00 3,759,213.00 3,813,517.00 3,817,005.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.17 -1.05 -0.46 -2.91 -0.67 -0.45 -1.12 -0.43 -0.27
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -100.00% 166.95% 662.71% -100.00% 0.00% 108.33%
EBITDA Growth		 63.58% -18.51% 30.85% -374.61% -210.24% 52.08% -229.88% 80.16% 54.86%
EBIT Growth		 21.38% 28.10% 35.24% -351.22% -43.73% 15.83% -229.88% 80.16% 54.86%
NOPAT Growth		 21.38% 28.10% 35.24% -351.22% -43.73% 15.83% -229.88% 80.16% 54.94%
Net Income Growth		 8.95% 27.73% 35.21% -297.78% -24.31% 16.09% -229.39% 80.09% 54.46%
EPS Growth		 8.95% 32.74% 62.70% -110.61% 36.19% 61.95% -138.30% 84.53% 59.70%
Operating Cash Flow Growth		 -32.34% 50.54% 20.19% 36.73% 44.91% -26.54% 15.82% 23.61% 75.43%
Free Cash Flow Firm Growth		 93.08% 77.65% 55.13% -5,636.27% -766.37% -109.82% -870.22% 83.94% 99.35%
Invested Capital Growth		 -64.11% -40.99% -27.39% 26.92% 7.80% 12.38% 48.14% -4.24% -33.12%
Revenue Q/Q Growth		 191.36% 0.00% 202.71% -100.00% 0.00% 185.71% -100.00% 0.00% 22.89%
EBITDA Q/Q Growth		 57.99% -329.13% 59.19% -545.03% 72.54% 33.71% -180.93% 61.20% 37.53%
EBIT Q/Q Growth		 13.79% -20.62% 32.73% -545.03% 72.54% 29.36% -163.64% 61.20% 37.53%
NOPAT Q/Q Growth		 13.79% -20.62% 32.73% -545.03% 72.54% 29.36% -163.64% 61.20% 37.63%
Net Income Q/Q Growth		 11.86% -4.58% 33.01% -544.23% 72.46% 29.41% -162.97% 61.05% 37.02%
EPS Q/Q Growth		 11.86% -7.62% 58.41% -491.49% 75.90% 35.82% -160.47% 61.61% 37.21%
Operating Cash Flow Q/Q Growth		 -99.82% 63.66% -137.40% 63.30% -73.98% 16.52% -57.91% 66.69% 44.05%
Free Cash Flow Firm Q/Q Growth		 -271.79% -228.00% 37.88% -1,481.75% 73.12% 20.57% -187.23% 73.82% 98.92%
Invested Capital Q/Q Growth		 21.75% 1.04% 2.02% 3.68% 1.27% 5.96% 42.01% -93.61% -26.08%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 35.00% 35.01% 35.00% 0.00% 30.00% 30.00% 0.00% 33.56% 32.44%
EBITDA Margin		 -6,173.55% -26,492.73% -3,571.78% 0.00% -7,174.72% -1,664.60% 0.00% -3,057.81% -1,554.43%
Operating Margin		 -13,325.32% -16,072.75% -3,571.78% 0.00% -7,174.72% -1,773.80% 0.00% -3,057.81% -1,551.76%
EBIT Margin		 -13,325.32% -16,072.75% -3,571.78% 0.00% -7,174.72% -1,773.80% 0.00% -3,057.81% -1,554.43%
Profit (Net Income) Margin		 -15,465.44% -16,174.14% -3,579.19% 0.00% -7,201.90% -1,779.32% 0.00% -3,071.60% -1,574.18%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 116.06% 100.63% 100.21% 100.08% 100.38% 100.31% 100.06% 100.45% 101.27%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -3,956.01% 701.76% 353.19% 487.03% 861.92% 983.91% 839.77% 402.01% 316.07%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -69.55% -331.81% -232.82% 0.00% -436.51% -253.66% 0.00% -836.35% -615.93%
Return on Assets (ROA)		 -80.72% -333.90% -233.30% 0.00% -438.16% -254.45% 0.00% -840.12% -623.76%
Return on Common Equity (ROCE)		 -3,956.01% 701.76% 353.19% 487.03% 861.92% 983.91% 839.77% 402.01% 316.07%
Return on Equity Simple (ROE_SIMPLE)		 777.80% 0.00% 312.16% 0.00% 0.00% 0.00% 1,008.95% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.10 -1.33 -0.89 -5.76 -1.58 -1.12 -2.95 -1.14 -0.71
NOPAT Margin		 -9,327.73% -11,250.92% -2,500.24% 0.00% -5,022.30% -1,241.66% 0.00% -2,140.47% -1,086.23%
Net Nonoperating Expense Percent (NNEP)		 -35.10% -69.61% 2,200.83% 1,377.31% -110.92% -62.67% 502.09% 218.64% 148.14%
Return On Investment Capital (ROIC_SIMPLE)		 - 63.23% 40.78% 256.64% 76.76% 217.03% 418.80% 49.87% 25.16%
Cost of Revenue to Revenue		 65.00% 64.99% 65.00% 0.00% 70.00% 70.00% 0.00% 66.44% 67.56%
SG&A Expenses to Revenue		 11,490.38% 13,459.75% 2,731.17% 0.00% 6,168.65% 1,533.26% 0.00% 2,193.14% 1,274.19%
R&D to Revenue		 1,869.94% 2,648.01% 875.61% 0.00% 1,036.07% 270.54% 0.00% 898.23% 310.01%
Operating Expenses to Revenue		 13,360.32% 16,107.75% 3,606.78% 0.00% 7,204.72% 1,803.80% 0.00% 3,091.37% 1,584.20%
Earnings before Interest and Taxes (EBIT)		 -1.57 -1.90 -1.28 -8.23 -2.26 -1.60 -4.21 -1.63 -1.02
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.73 -3.13 -1.28 -8.23 -2.26 -1.50 -4.21 -1.63 -1.02
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 854.25 40.95 487.03 560.67 709.54 226.23 346.61 244.64 292.01
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 768.94 34.87 486.09 561.49 707.80 216.41 349.88 246.00 293.90
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 -0.12 -0.05 -0.03 -0.02 -0.01 0.00 -0.57 -0.10 -0.14
Long-Term Debt to Equity		 -0.02 0.00 0.00 0.00 0.00 0.00 -0.21 -0.02 0.00
Financial Leverage		 -9.59 0.75 -0.01 -0.07 0.39 0.57 -0.13 -0.09 -0.08
Leverage Ratio		 14.12 -1.21 -0.48 -0.24 -0.82 -0.81 -0.55 -0.26 -0.20
Compound Leverage Factor		 16.38 -1.22 -0.49 -0.24 -0.82 -0.81 -0.55 -0.27 -0.20
Debt to Total Capital		 -13.77% -5.07% -3.61% -2.27% -1.07% 0.00% -129.90% -10.85% -15.99%
Short-Term Debt to Total Capital		 -11.48% -5.07% -3.61% -2.27% -1.07% 0.00% -82.15% -8.80% -15.58%
Long-Term Debt to Total Capital		 -2.29% 0.00% 0.00% 0.00% 0.00% 0.00% -47.75% -2.05% -0.41%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 113.77% 105.07% 103.61% 102.27% 101.07% 100.00% 229.90% 110.85% 115.99%
Debt to EBITDA		 -0.02 -0.01 -0.01 0.00 0.00 0.00 -0.06 -0.03 -0.05
Net Debt to EBITDA		 0.19 0.02 0.01 0.00 0.01 0.00 -0.02 -0.02 -0.05
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 0.00 0.00
Debt to NOPAT		 -0.02 -0.02 -0.02 -0.01 0.00 0.00 -0.08 -0.04 -0.08
Net Debt to NOPAT		 0.24 0.03 0.01 -0.01 0.01 0.00 -0.03 -0.04 -0.07
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.01 0.00
Altman Z-Score		 -81.66 -327.35 -216.69 -368.81 -389.43 -110.22 -151.66 -288.13 -363.25
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.61 0.15 0.23 0.17 0.17 0.80 0.39 0.14 0.08
Quick Ratio		 0.47 0.10 0.05 0.00 0.07 0.76 0.20 0.01 0.02
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.20 -0.67 -0.41 -6.55 -1.76 -1.40 -4.02 -1.05 -0.01
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -0.81 -55.73 -156.47 -968.24 -205.75 -281.77 -1,674.31 -142.94 -0.88
Operating Cash Flow to Interest Expense		 -7.80 -59.82 -641.90 -92.17 -126.75 -182.42 -595.93 -64.73 -20.57
Operating Cash Flow Less CapEx to Interest Expense		 -7.80 -59.82 -641.90 -92.17 -126.75 -182.42 -595.93 -64.73 -20.57
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.01 0.02 0.07 0.09 0.06 0.14 0.11 0.27 0.40
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 5.20 52.88 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.01 0.02 0.05 0.03 0.07 0.11 0.11 0.11 0.13
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 70.18 6.90 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 27,269.11 18,846.54 7,378.89 11,579.01 5,404.54 3,215.53 3,373.81 3,185.62 2,875.18
Cash Conversion Cycle (CCC)		 -27,269.11 -18,846.54 -7,378.89 -11,579.01 -5,334.36 -3,208.63 -3,373.81 -3,185.62 -2,875.18
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -2.30 -2.27 -2.23 -2.15 -2.12 -1.99 -1.16 -2.24 -2.82
Invested Capital Turnover		 -0.01 -0.01 -0.03 -0.02 -0.04 -0.07 -0.07 -0.08 -0.08
Increase / (Decrease) in Invested Capital		 -0.90 -0.66 -0.48 0.79 0.18 0.28 1.07 -0.09 -0.70
Enterprise Value (EV)		 12 0.96 31 33 56 34 43 43 61
Market Capitalization		 14 1.13 31 33 56 36 42 43 61
Book Value per Share		 ($0.10) ($1.21) ($0.82) ($0.81) ($0.62) ($0.15) ($0.43) ($0.67) ($0.86)
Tangible Book Value per Share		 ($0.10) ($1.21) ($0.82) ($0.81) ($0.62) ($0.15) ($0.43) ($0.67) ($0.86)
Total Capital		 -0.96 -2.10 -2.19 -2.24 -2.06 -0.51 -0.70 -2.29 -2.83
Total Debt		 0.13 0.11 0.08 0.05 0.02 0.00 0.91 0.25 0.45
Total Long-Term Debt		 0.02 0.00 0.00 0.00 0.00 0.00 0.34 0.05 0.01
Net Debt		 -1.35 -0.17 -0.06 0.05 -0.14 -1.54 0.40 0.24 0.40
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.60 -2.50 -2.43 -2.33 -2.28 -1.95 -1.53 -2.36 -2.95
Debt-free Net Working Capital (DFNWC)		 -1.12 -2.23 -2.30 -2.33 -2.12 -0.41 -1.01 -2.35 -2.89
Net Working Capital (NWC)		 -1.23 -2.34 -2.37 -2.38 -2.14 -0.41 -1.59 -2.55 -3.33
Net Nonoperating Expense (NNE)		 0.72 0.58 0.39 2.48 0.69 0.48 1.27 0.50 0.32
Net Nonoperating Obligations (NNO)		 -1.20 -0.07 0.04 0.15 -0.03 -1.48 0.46 0.30 0.47
Total Depreciation and Amortization (D&A)		 0.84 -1.23 0.00 0.00 0.00 0.10 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -16,406.49% -9,056.85% -3,841.39% -3,923.84% -2,884.70% -1,239.55% -1,258.50% -1,348.08% -1,410.66%
Debt-free Net Working Capital to Revenue		 -7,039.65% -8,064.52% -3,622.61% -3,919.68% -2,682.97% -258.48% -832.83% -1,342.46% -1,383.29%
Net Working Capital to Revenue		 -7,736.17% -8,449.12% -3,747.32% -4,005.52% -2,710.85% -258.48% -1,308.46% -1,457.80% -1,594.48%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.05) ($1.13) ($0.47) ($2.78) ($0.67) ($0.43) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 1.82M 1.69M 2.83M 3.37M 3.55M 3.76M 3.81M 3.82M 3.89M
Adjusted Diluted Earnings per Share		 ($1.05) ($1.13) ($0.47) ($2.78) ($0.67) ($0.43) ($1.12) ($0.43) ($0.27)
Adjusted Weighted Average Diluted Shares Outstanding		 1.82M 1.69M 2.83M 3.37M 3.55M 3.17M 3.75M 3.81M 3.82M
Adjusted Basic & Diluted Earnings per Share		 ($1.05) ($1.13) ($0.47) ($2.78) ($0.67) ($0.43) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.74M 1.69M 2.75M 2.96M 3.41M 3.76M 3.81M 3.82M 3.89M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.10 -1.33 -0.89 -5.76 -1.58 -1.12 -2.95 -1.14 -0.71
Normalized NOPAT Margin		 -9,327.73% -11,250.92% -2,500.24% 0.00% -5,022.30% -1,241.66% 0.00% -2,140.47% -1,086.23%
Pre Tax Income Margin		 -15,465.44% -16,174.14% -3,579.19% 0.00% -7,201.90% -1,779.32% 0.00% -3,071.60% -1,574.18%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -6.23 -158.52 -481.99 -1,216.32 -264.02 -321.53 -1,753.66 -221.86 -78.72
NOPAT to Interest Expense		 -4.36 -110.97 -337.40 -851.42 -184.82 -225.07 -1,227.56 -155.30 -55.01
EBIT Less CapEx to Interest Expense		 -6.23 -158.52 -481.99 -1,216.32 -264.02 -321.53 -1,753.66 -221.86 -78.72
NOPAT Less CapEx to Interest Expense		 -4.36 -110.97 -337.40 -851.42 -184.82 -225.07 -1,227.56 -155.30 -55.01
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ZIVO Bioscience’s latest quarter shows a business that is generating some revenue, but still operating at a significant loss and carrying a strained balance sheet. In Q3 2025, revenue rose to $65.6 thousand from $53.4 thousand in Q2 2025 and $31.5 thousand in Q3 2024, but the company still reported a net loss of $1.0 million. Cash from operations was also negative, and liabilities remain far larger than assets.

Revenue trend: Top-line results have improved year over year on a quarterly basis, but the absolute level of revenue is still very small. That means ZIVO remains far from scale, and even modest operating expenses are enough to push the company deep into the red.

Profitability trend: Losses have narrowed from the very large losses seen in early 2025 and late 2024, but ZIVO is still not close to break-even. In Q3 2025, operating expenses of $1.0 million dwarfed gross profit of just $21.3 thousand, resulting in an operating loss of $1.0 million and negative diluted EPS of $0.27.

Cash flow trend: Operating cash flow improved versus Q2 2025, but it was still negative at $266.6 thousand. The company generated $47.4 thousand of net cash during the quarter, but that was supported by financing activity rather than self-funding from operations.

Balance sheet trend: ZIVO ended Q3 2025 with only $57.2 thousand in cash and equivalents, down sharply from $517.2 thousand at the end of Q1 2025. Total current liabilities of $3.6 million vastly exceed total current assets of $281.4 thousand, pointing to a weak near-term liquidity position.

Shareholder equity remains deeply negative: Total common equity was negative $3.3 million in Q3 2025. That has been negative for several quarters, which is a sign the company has accumulated substantial losses over time.

  • Q3 2025 revenue improved year over year, rising to $65.6 thousand from $31.5 thousand in Q3 2024.
  • Gross profit remained positive at $21.3 thousand, showing the company can still produce some margin on sales.
  • Operating cash flow improved sequentially versus Q2 2025, narrowing from a $476.4 thousand outflow to a $266.6 thousand outflow.
  • Net loss narrowed sharply from $4.2 million in Q1 2025 to $1.0 million in Q3 2025.
  • The company still relies on financing activity to support liquidity, rather than funding itself through operations.
  • Debt levels are not huge in absolute terms, but short-term debt and other current obligations remain meaningful relative to the company’s cash position.
  • R&D spending remains present, which suggests ZIVO is still investing in product development despite its small revenue base.
  • Operating expenses remain far above revenue, with SG&A and R&D combined at more than $1.0 million in Q3 2025.
  • Cash on hand is very low at $57.2 thousand, increasing liquidity risk.
  • Current liabilities far exceed current assets, indicating a weak short-term balance sheet and possible dependence on external capital.

Bottom line: ZIVO Bioscience has shown some sequential and year-over-year improvement in revenue and losses, but the company still looks highly speculative. Until revenue becomes much larger and operating losses narrow more consistently, the business will likely remain dependent on outside financing and vulnerable to dilution or balance-sheet pressure.

07/22/26 09:39 PM ETAI Generated. May Contain Errors.

ZIVO Bioscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ZIVO Bioscience's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

ZIVO Bioscience's net income appears to be on an upward trend, with a most recent value of -$13.38 million in 2024, falling from $680.81 thousand in 2014. The previous period was -$7.78 million in 2023.

ZIVO Bioscience's total operating income in 2024 was -$13.36 million, based on the following breakdown:
  • Total Gross Profit: $48.95 thousand
  • Total Operating Expenses: $13.41 million

Over the last 10 years, ZIVO Bioscience's total revenue changed from $1.48 million in 2014 to $157.22 thousand in 2024, a change of -89.4%.

ZIVO Bioscience's total liabilities were at $2.16 million at the end of 2024, a 21.9% decrease from 2023, and a 66.7% decrease since 2014.

In the past 10 years, ZIVO Bioscience's cash and equivalents has ranged from $1.38 thousand in 2014 to $8.90 million in 2021, and is currently $1.54 million as of their latest financial filing in 2024.

Over the last 10 years, ZIVO Bioscience's book value per share changed from -0.05 in 2014 to -0.15 in 2024, a change of 193.3%.


Related Companies

Financial statements for NASDAQ:ZIVO last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
America’s answer to universal basic income
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
TSM just handed Trump's secretive AI project $100 billion
Taiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion a...
InvestorPlace | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Elon is about to dominate the biggest arms race in tech history
Microsoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...
The Oxford Club | Sponsoredtc pixel
Wall Street legend put 60% in one stock — here’s the ticker
One of America's most famous investors put 60% of his fund into a single stock - and Whitney Tilson of Stansbe...
Stansberry Research | Sponsoredtc pixel
It all happens tonight.
Tonight, trader Sean Allison is hosting a live session to walk through his Zero-Dollar Trade Advantage strateg...
Trade Thirsty | Sponsoredtc pixel